荣昌生物
(688331)
| 流通市值：395.79亿 | | | 总市值：627.76亿 |
| 流通股本：3.56亿 | | | 总股本：5.64亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 5,853,293,736.77 | 656,214,449.91 | 3,251,051,061.93 | 1,719,833,029.78 |
| 营业总成本 | 1,521,635,103.35 | 696,878,783.64 | 3,189,186,995.42 | 2,268,418,316.44 |
| 其他经营收益 | | | | |
| 营业利润 | 4,668,662,367.53 | 330,170,273.88 | 722,605,872.09 | -537,269,154.58 |
| 利润总额 | 4,662,874,654 | 328,493,639.92 | 710,398,488.34 | -550,700,575.38 |
| 净利润 | 4,662,283,356.3 | 328,007,104.92 | 709,649,797.14 | -550,700,575.38 |
| 每股收益 | | | | |
| 其他综合收益 | -7,954,798.65 | 330,879.64 | 52,652,126.87 | 49,592,840.32 |
| 综合收益总额 | 4,654,328,557.65 | 328,337,984.56 | 762,301,924.01 | -501,107,735.06 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 6,622,716,626.74 | 4,112,057,982.68 | 3,981,885,253.42 | 2,719,142,876.94 |
| 非流动资产: | | | | |
| 非流动资产合计 | 3,224,533,299.08 | 3,253,135,923.08 | 3,266,187,035.55 | 3,257,987,007.18 |
| 资产总计 | 9,847,249,925.82 | 7,365,193,905.76 | 7,248,072,288.97 | 5,977,129,884.12 |
| 流动负债: | | | | |
| 流动负债合计 | 1,361,661,461.26 | 2,600,531,250.45 | 2,787,458,494 | 2,832,798,494.68 |
| 非流动负债: | | | | |
| 非流动负债合计 | 171,513,358.28 | 836,198,001.62 | 851,792,137.4 | 824,248,325.8 |
| 负债合计 | 1,533,174,819.54 | 3,436,729,252.07 | 3,639,250,631.4 | 3,657,046,820.48 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 8,314,075,106.28 | 3,928,464,653.69 | 3,608,821,657.57 | 2,320,083,063.64 |
| 股东权益合计 | 8,314,075,106.28 | 3,928,464,653.69 | 3,608,821,657.57 | 2,320,083,063.64 |
| 负债和股东权益合计 | 9,847,249,925.82 | 7,365,193,905.76 | 7,248,072,288.97 | 5,977,129,884.12 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 5,808,957,860.03 | 770,608,371.94 | 2,719,241,387.37 | 2,255,935,870.87 |
| 经营活动现金流出小计 | 1,595,134,921.55 | 759,290,367.99 | 2,666,289,491.99 | 2,038,878,436.93 |
| 经营活动产生的现金流量净额 | 4,213,822,938.48 | 11,318,003.95 | 52,951,895.38 | 217,057,433.94 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,859,508,131.05 | 664,553,376.08 | 2,164,959,117.36 | 1,062,794,914.72 |
| 投资活动现金流出小计 | 3,885,020,357.32 | 643,973,532.19 | 2,370,607,014.35 | 1,342,340,631.06 |
| 投资活动产生的现金流量净额 | -2,025,512,226.27 | 20,579,843.89 | -205,647,896.99 | -279,545,716.34 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 359,092,230.37 | 191,190,318.71 | 2,849,724,870.07 | 2,117,271,291.07 |
| 筹资活动现金流出小计 | 2,161,352,827.97 | 273,722,902.49 | 2,297,766,584.86 | 1,746,302,543.74 |
| 筹资活动产生的现金流量净额 | -1,802,260,597.6 | -82,532,583.78 | 551,958,285.21 | 370,968,747.33 |
| 汇率变动对现金及现金等价物的影响 | -11,754,022.02 | -5,332,945.61 | -4,193,799.09 | -620,373.83 |
| 现金及现金等价物净增加额 | 374,296,092.59 | -55,967,681.55 | 395,068,484.51 | 307,860,091.1 |
| 期末现金及现金等价物余额 | 1,528,894,620.52 | 1,098,630,846.38 | 1,154,598,527.93 | 1,067,390,134.52 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 374,296,092.59 | - | 395,068,484.51 | - |
最新报告期：2026-09-25| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 西部证券 | 李梦园 | 7.40 | 1.37 | 2.19 | 2026-09-25 |
| 东海证券 | 杜永宏 | 6.92 | 1.10 | 2.31 | 2026-09-03 |
| 浙商证券 | 郭双喜 | 7.20 | 0.92 | 1.60 | 2026-08-30 |
| 华泰证券 | 代雯,李航,袁中平 | 8.41 | 0.85 | 1.87 | 2026-08-25 |
| 华泰证券 | 代雯,李航,袁中平 | 7.47 | 0.83 | 1.94 | 2026-08-06 |